Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Purpose Spironolactone (SP) is an effective treatment for polycystic ovary syndrome (PCOS), but it is often associated with menstrual abnormalities whose mechanism is still under investigation. In this study, we investigated the serum sex steroids and endometrial thickness in 30 PCOS patients, before and after one-month 100 mg SP treatment.Methods Serum FSH, LH, estradiol, progesterone and endometrial thickness were evaluated at the 14th and 16th day of the menstrual cycle, before and during short-term SP treatment. According to the presence (15 cases) or absence (15 cases) of menstrual bleeding at the 14th day during SP, the patients were divided into two groups, which were then compared using a two-tailed Student's t test.Results Serum estradiol and endometrial thickness were lower than pretreatment at both determinations in all patients, but patients with bleeding had significantly lower estradiol values than non-bleeding ones, both before and after therapy. Endometrial thickness was significantly lower in the bleeding group compared with non-bleeding group only at the 16th day of the cycle. These differences were significant, even though the values of estradiol and endometrial thickness remained in the normal range.Conclusions SP therapy can reduce the values of estradiol and the endometrial thickness in patients with PCOS compared with pretreatment, but PCOS patients with bleeding had pretreatment estradiol values lower than the patients who did not complain of this side effect. Intermenstrual abnormalities may represent the low estrogen impregnation of endometrium due to SP, whose mechanism is complex, involving several factors, such as the effects of some metabolites of SP on estradiol and progesterone production, on their receptors, and the individual metabolism of SP in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The adverse effects are intermenstrual bleedings, related to a selective progesterone receptor modulator effect of spironolactone [75].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [75]
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Men at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Ehrmann, D. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041536 · Cited by 1,881
Epidemiology, diagnosis, and management of polycystic ovary syndrome
Sirmans, S., & Pate, K. (2013) · Clinical Epidemiology · doi:10.2147/clep.s37559 · Cited by 1,302
Antiandrogenic Effect of Spirolactones: Mechanism of Action
CORVOL, P., MICHAUD, A., MENARD, J., FREIFELD, M., & MAHOUDEAU, J. (1975) · Endocrinology · doi:10.1210/endo-97-1-52 · Cited by 259
A Novel Use of Spironolactone: Treatment of Hirsutism
SHAPIRO, G., & EVRON, S. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-3-429 · Cited by 127
Spironolactone as a single agent for long‐term therapy of hirsute patients
Spritzer, P. M., Lisboa, K. O., Mattiello, S., & Lhullier, F. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00982.x · Cited by 123
Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome
Cascella, T., Palomba, S., Tauchmanovà, L., Manguso, F., Di Biase, S., Labella, D., Giallauria, F., Vigorito, C., Colao, A., Lombardi, G., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0399 · Cited by 120 · cited 1×
“Some evidence has shown that in many PCOS patients plasma aldosterone, aldosterone to plasma renin activity (PRA) ratio and mean blood pressure are higher than in healthy controls, thus increasing the risk of cardiovascular complications particularly after menopause [11, 12].”
BackgroundEffect of Spironolactone on Sex Hormones in Man
STRIPP, B., TAYLOR, A. A., BARTTER, F. C., GILLETTE, J. R., LORIAUX, D. L., EASLEY, R., & MENARD, R. H. (1975) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-41-4-777 · Cited by 102
Side-Effects of Spironolactone Therapy in the Hirsute Woman
Helfer, E. L., Miller, J. L., & Rose, L. I. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-66-1-208 · Cited by 84 · cited 1×
“20–50 % of PCOS patients taking SP have menstrual abnormalities, such as intermenstrual bleeding, metrorrhagias or amenorrhea, and the underlying mechanism is still under investigation [13].”
BackgroundTreatment of polycystic ovary syndrome with spironolactone plus licorice
Armanini, D., Castello, R., Scaroni, C. M., Bonanni, G., Faccini, G., Pellati, D., Bertoldo, A., Fiore, C., & Moghetti, P. (2006) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2006.10.013 · Cited by 75 · cited 1×
“The interaction of all these mechanisms explains why SP usually does not increase serum androgen concentration, as expected for a pure AR antagonism [9].”
BackgroundSelf-citationINTERACTION OF SPIRONOLACTONE WITH OESTRADIOL RECEPTORS IN CYTOSOL
LEVY, J., BURSHELL, A., MARBACH, M., AFLLALO, L., & GLICK, S. M. (1980) · Journal of Endocrinology · doi:10.1677/joe.0.0840371 · Cited by 46 · cited 2×
“This double action could also reduce E2 secretion due to the negative feedback by FSH as a consequence of agonistic action of SP in the pituitary [18, 19].”
BackgroundArmanini, D., Bordin, L., Donà, G., Sabbadin, C., Bakdounes, L., Ragazzi, E., Giorgino, F. L., & Fiore, C. (2012) · Steroids · doi:10.1016/j.steroids.2012.02.010 · Cited by 45 · cited 2×
“Some evidence has shown that in many PCOS patients plasma aldosterone, aldosterone to plasma renin activity (PRA) ratio and mean blood pressure are higher than in healthy controls, thus increasing the risk of cardiovascular complications particularly after menopause [11, 12].”
BackgroundSelf-citationMoghetti, P., Castello, R., Zamberlan, N., Rossini, M., Gatti, D., Negri, C., Tosi, F., Muggeo, M., & Adámi, S. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.4.5606 · Cited by 43 · cited 1×
“This double action could also reduce E2 secretion due to the negative feedback by FSH as a consequence of agonistic action of SP in the pituitary [18, 19].”
Aldosterone receptor blockers spironolactone and canrenone: Two multivalent drugs
Armanini, D., Sabbadin, C., Donà, G., Clari, G., & Bordin, L. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.896901 · Cited by 41 · cited 1×
“It is well known that SP reduces the synthesis of aldosterone in primary aldosteronism, at least in the first period of treatment when renin is still suppressed, and SP bodies have been described in the adrenal of patients with primary aldosteronism [21].”
BackgroundSelf-citationSundar, S., & Dickinson, P. D. (2012) · BMJ Case Reports · doi:10.1136/bcr.11.2011.5238 · Cited by 40 · cited 1×
“A similar mechanism has been reported at the level of the AR, where SP can exhibit both agonistic and mostly antagonistic activity, modulated by the cellular and molecular environment [17].”
BackgroundAntiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism
Messina, M., Manieri, C., Biffignandi, P. M., Massucchetti, C., Novi, R. F., & Molinatti, G. M. (1983) · Journal of Endocrinological Investigation · doi:10.1007/bf03350556 · Cited by 35
ARMANINI, D., KARBOWIAK, I., GOI, A., MANTERO, F., & FUNDER, J. W. (1985) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1985.tb01090.x · Cited by 29 · cited 1×
“The main active metabolite of SP is canrenone, which is more selective for MR than for AR; therefore the antiandrogenic effect is linked to other metabolites of SP with different antimineralocorticoid and/or antiandrogenic activity [1].”
BackgroundSelf-citationAntiandrogenic Effects of Spironolactone: Hormonal and Ultrastructural Studies in Dogs and Men
Baba, S., Murai, M., Jitsukawa, S., Hata, M., & Tazaki, H. (1978) · The Journal of Urology · doi:10.1016/s0022-5347(17)57495-9 · Cited by 27
ORAL PROGESTATIONAL ACTIVITY OF SPIRONOLACTONE1
Schane, H. P., & POTTS, G. O. (1978) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-47-3-691 · Cited by 25
The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol.
Fernandez, M., Carter, G., & Palmer, T. (1983) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1983.tb01470.x · Cited by 10 · cited 4×
“However, therapeutic doses of SP (as for example in PCOS) have also been described to partially inhibit P binding to uterine receptors, causing polymenorrhea [16].”
BackgroundInfluential
Research works printed but not linked: 1
- Smals AGH, Kloppenborg PWC, Hoefnagels WH, Drayer JIM, Benraad ThJ (1978) Pituitary and gonadal function in high-dose spironolactone-treated premenopausal women. Aldosterone antagonists in clinical medicine. Proceedings of the Searle symposium, Nice 303–307
Cited by
Armanini, D., Boscaro, M., Bordin, L., & Sabbadin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084110 · Cited by 324
“The adverse effects are intermenstrual bleedings, related to a selective progesterone receptor modulator effect of spironolactone [75].”
BackgroundSelf-citationIslam, H., Masud, J., Islam, Y. N., & Haque, F. K. M. (2022) · Women s Health · doi:10.1177/17455057221117966 · Cited by 133
Licorice: From Pseudohyperaldosteronism to Therapeutic Uses
Sabbadin, C., Bordin, L., Donà, G., Manso, J., Avruscio, G., & Armanini, D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00484 · Cited by 76
“It is worth noting that licorice can also reduce the prevalence on intermenstrual bleeding occurring in about 20–50% of women taking spironolactone (43).”
BackgroundSelf-citationSpironolactone in the treatment of polycystic ovary syndrome
Armanini, D., Andrisani, A., Bordin, L., & Sabbadin, C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1215430 · Cited by 53
Self-citationYuan, J., Li, Z., Yu, Y., Wang, X., & Zhao, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1520695 · Cited by 51
“Spironolactone improves hirsutism (24) but may cause intermenstrual bleeding (25).”
Metadata
- Authors
- Sabbadin, C., Andrisani, A., Zermiani, M., Donà, G., Bordin, L., Ragazzi, E., Boscaro, M., Ambrosini, G., & Armanini, D.
- Affiliations
- University of Padua (IT)
- Corresponding author
- Armanini, D.
- Venue
- Journal of Endocrinological Investigation
- Published
- 2016-04-12
- Volume
- 39
- Issue
- 9
- Pages
- 1015-1021
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- OpenAlex
- W2341339272
- Cited by
- 33
- References
- 21
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 3 · 2019: 3 · 2018: 3 · 2017: 1 · 2016: 3
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Endocrinological Investigation (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Università degli Studi di Padova
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- spironolactone, polycystic ovary syndrome, metrorrhagia, menstrual disorders, estradiol, endometrial thickness, normal body mass index
- MeSH terms
- Adult, Mineralocorticoid Receptor Antagonists, Female, Humans, Menstrual Cycle, Metrorrhagia, Polycystic Ovary Syndrome, Spironolactone, Ultrasonography, Body Mass Index, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.